

Humanigen, Inc.

11:35 07 Jul 2020

Humanigen strengthens leadership team with three new executive appointments

Humanigen Inc (OTCMKTS:HGEN) bolstered its leadership team with the addition of three new executives, it reported Tuesday.

The California-based biopharmaceutical company has appointed Dale Chappell as chief scientific officer, David Tousley as chief accounting and administrative officer, corporate secretary and treasurer and Omar Ahmed as senior vice president, clinical, medical and scientific affairs.

The appointments provide Humanigen with both continuity and bench strength as the firm advances work on lenzilumab, which is being investigated as a potential treatment for cytokine storms caused by the coronavirus infection.

READ: Humanigen reveals first patient has been infused in ZUMA-19 study

Chappell is a former Howard Hughes Medical Institute fellow at the National Cancer Institute, studying tumor immunology and publishing in the field of T-cell therapy, immunology pathways, and GM-CSF.

Tousley has held C-suite roles at companies including Pasteur Merieux Connaught (now Sanofi Pasteur), AVAX Technologies Inc and DARA Biosciences.

Ahmed has over 20 years of executive leadership experience, including advancing Janssen's \$10 billion global immunology portfolio from early development to late-stage development as well as leadership positions at Novartis and Roche Pharmaceuticals.

"We are pleased that both Dr Chappell and Mr Tousley, who have previously operated in interim capacities with the company, have joined us as full-time members of the Humanigen team," Humanigen CEO Cameron Durrant said in a statement.

"Their appointments, along with Dr Ahmed's promotion, provide us with continuity and ongoing scientific and operational bench strength as we move the company forward. Filling these key leadership roles with proven executives who are highly regarded within the biotechnology sector, and who have been deeply involved with the strategic direction of our company, is a next step in our plan to rapidly grow into an organization committed to bringing important therapies to patients around the globe."

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

1 Year Share Price Graph



December 2019 April 2020 September 2020

Share Information

Code: HGEN
Listing: OTCQB
Sector: Pharma & Biotech
Website: www.humanigen.com

Company Synopsis:

Humanigen develops biologics to improve CAR-T and other breakthrough oncology treatments. Lenzilumab is a product that has the potential to both improve the efficacy and safety associated with CAR-T therapy in oncology. We are developing lenzilumab in close collaboration with the leading and most experienced centers in the CAR-T field. We are exploring partnerships with established and emerging CAR-T companies.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).